フィナステリド市場：適応症別、流通チャネル別-2025-2030年の世界予測

フィナステリド市場は、2023年に1億1,968万米ドルと評価され、2024年には1億2,288万米ドルに達すると予測され、CAGR 2.81％で成長し、2030年には1億4,540万米ドルに達すると予測されています。

フィナステリドは、主に前立腺肥大症（BPH）と男性型脱毛症の治療に使用される薬で、泌尿器科と皮膚科の2つの治療用途があることから注目を集めています。フィナステリドが必要とされる背景には、男性の高齢化に伴う前立腺肥大症の増加や、発毛剤に対する需要の高まりがあります。その用途は、BPH管理のための経口錠剤と脱毛治療のための局所製剤の両方に及ぶ。最終用途の範囲は、病院、専門クリニック、小売薬局などのヘルスケア部門を包含しており、いずれも国民にフィナステリドを調剤する上で極めて重要です。市場成長の主な原動力は、人口動態の高齢化、男性型脱毛症の有病率の増加、ヘルスケア意識の高まりに加え、製剤技術の進歩です。最新の成長機会としては、医療インフラが改善しつつあるアジア太平洋やラテンアメリカを中心とした地理的アクセスの拡大が挙げられます。企業は、市場でのプレゼンスを拡大するために戦略的合併を行うことで、これを利用することができます。しかし、市場競争を激化させる特許切れや代替療法の利用可能性という課題もあります。加えて、性機能障害などの副作用が受容を制限する可能性もあります。また、さまざまな地域における規制上のハードルも課題となっています。技術革新の有望な分野としては、薬剤の有効性を向上させ副作用を最小限に抑えるための先進デリバリーシステムの開発、治療効果を高めるための併用療法の模索、ターゲットを絞ったマーケティング戦略のためのAI主導型アナリティクスの統合などが挙げられます。さらに、フィナステリドで治療される疾患の遺伝的素因に関する調査への注目が高まれば、新たな市場セグメントを開拓できる可能性があります。全体として、フィナステリド市場はダイナミックであり、戦略的拡大やイノベーションによる成長の可能性を秘めているが、規制状況や消費者の認識を慎重に見極め、バランスの取れたアプローチで市場の潜在力を最大限に活用する必要があります。

市場力学：急速に進化するフィナステリド市場の主要市場インサイトを公開

フィナステリド市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 男性型脱毛症および前立腺疾患の有病率の増加
  • 市場アクセシビリティを高める支援的な規制政策
• 市場抑制要因
  • 生産拡張性に影響する原料不足
• 市場機会
  • フィナステリドの生産技術の進歩
  • 治療用途におけるフィナステリドの大幅な拡大
• 市場の課題
  • 熟練労働者の不足

ポーターのファイブフォース：フィナステリド市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、フィナステリド市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：フィナステリド市場における外部からの影響の把握

外部マクロ環境要因は、フィナステリド市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析フィナステリド市場における競合情勢の把握

フィナステリド市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスフィナステリド市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、フィナステリド市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨フィナステリド市場における成功への道筋を描く

フィナステリド市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 男性型脱毛症および前立腺疾患の増加
    • 市場へのアクセス性を高める支援的な規制政策
  • 抑制要因
    • 原材料不足が生産の拡張性に影響
  • 機会
    • フィナステリドの生産技術の進歩
    • 治療用途におけるフィナステリドの大幅な拡大
  • 課題
    • 熟練労働者の不足
• 市場セグメンテーション分析
  • 適応症：男性型脱毛症におけるフィナステリドの採用率が高く、長期治療の選択肢となる
  • 流通チャネル：プライバシーと利便性を求める患者にとって便利な選択肢としてのオンライン薬局の出現
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 フィナステリド市場適応症別

• 男性型脱毛症
• 前立腺肥大症

第7章 フィナステリド市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第8章 南北アメリカのフィナステリド市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域のフィナステリド市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカのフィナステリド市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ZydusがフィナステリドとタダラフィルカプセルのUSFDA承認を取得
  • Zydus Lifesciences、英国を拠点とするLiqmeds Groupの買収により世界展開を拡大
  • ブルーウォーター・ワクチンズ、ヴェラス・ファーマシューティカルズのエンタッドフィ・カプセル部門を買収
• 戦略分析と提言

企業一覧

• Accord Healthcare US. by Intas Pharmaceuticals
• Apotex Inc.
• Aurobindo Pharma USA, Inc.
• Camber Pharmaceuticals, Inc. by Hetero Labs Limited
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Endo, Inc.
• Hanmi Pharmaceutical Co., LTD.
• Merck KGaA
• Niksan Life Sciences Private Limited
• Sun Pharmaceutical Industries Limited
• Teva Pharmaceuticals USA, Inc.
• Torrent Pharmaceuticals Ltd.
• Veru Inc.
• Viatris Inc.
• WELLONA PHARMACEUTICAL PRIVATE LIMITED
• Zydus Group.

LIST OF FIGURES

• FIGURE 1. FINASTERIDE MARKET RESEARCH PROCESS
• FIGURE 2. FINASTERIDE MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL FINASTERIDE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL FINASTERIDE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL FINASTERIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL FINASTERIDE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL FINASTERIDE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS FINASTERIDE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS FINASTERIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES FINASTERIDE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES FINASTERIDE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC FINASTERIDE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC FINASTERIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA FINASTERIDE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA FINASTERIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. FINASTERIDE MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. FINASTERIDE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. FINASTERIDE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL FINASTERIDE MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL FINASTERIDE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL FINASTERIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. FINASTERIDE MARKET DYNAMICS
• TABLE 7. GLOBAL FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL FINASTERIDE MARKET SIZE, BY ANDROGENETIC ALOPECIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL FINASTERIDE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL FINASTERIDE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. AMERICAS FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS FINASTERIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 17. ARGENTINA FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 18. ARGENTINA FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 19. BRAZIL FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 20. BRAZIL FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 21. CANADA FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 22. CANADA FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 23. MEXICO FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 24. MEXICO FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 25. UNITED STATES FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 27. UNITED STATES FINASTERIDE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 28. ASIA-PACIFIC FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 30. ASIA-PACIFIC FINASTERIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 31. AUSTRALIA FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 32. AUSTRALIA FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 33. CHINA FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 34. CHINA FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. INDIA FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 36. INDIA FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 37. INDONESIA FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 38. INDONESIA FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. JAPAN FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 40. JAPAN FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. MALAYSIA FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 42. MALAYSIA FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 43. PHILIPPINES FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 44. PHILIPPINES FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 45. SINGAPORE FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 46. SINGAPORE FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. SOUTH KOREA FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 48. SOUTH KOREA FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. TAIWAN FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 50. TAIWAN FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. THAILAND FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 52. THAILAND FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 53. VIETNAM FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. VIETNAM FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. EUROPE, MIDDLE EAST & AFRICA FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 57. EUROPE, MIDDLE EAST & AFRICA FINASTERIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 58. DENMARK FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 59. DENMARK FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 60. EGYPT FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 61. EGYPT FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 62. FINLAND FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. FINLAND FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. FRANCE FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 65. FRANCE FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 66. GERMANY FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 67. GERMANY FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 68. ISRAEL FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 69. ISRAEL FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. ITALY FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 71. ITALY FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 72. NETHERLANDS FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 73. NETHERLANDS FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 74. NIGERIA FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. NIGERIA FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. NORWAY FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 77. NORWAY FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. POLAND FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. POLAND FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 80. QATAR FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 81. QATAR FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 82. RUSSIA FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 83. RUSSIA FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 84. SAUDI ARABIA FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 85. SAUDI ARABIA FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH AFRICA FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH AFRICA FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. SPAIN FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 89. SPAIN FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 90. SWEDEN FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. SWEDEN FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. SWITZERLAND FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 93. SWITZERLAND FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 94. TURKEY FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 95. TURKEY FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. UNITED ARAB EMIRATES FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 97. UNITED ARAB EMIRATES FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. UNITED KINGDOM FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 99. UNITED KINGDOM FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 100. FINASTERIDE MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 101. FINASTERIDE MARKET, FPNV POSITIONING MATRIX, 2023

The Finasteride Market was valued at USD 119.68 million in 2023, expected to reach USD 122.88 million in 2024, and is projected to grow at a CAGR of 2.81%, to USD 145.40 million by 2030.

Finasteride, a medication primarily used to treat benign prostatic hyperplasia (BPH) and male pattern baldness, has garnered attention due to its dual therapeutic applications in urology and dermatology. The necessity for Finasteride arises from the growing incidence of BPH in aging males and increased demand for hair regrowth solutions. Its application extends to both oral tablets for BPH management and topical formulations for hair loss treatment. End-use scope encompasses healthcare sectors like hospitals, specialty clinics, and retail pharmacies, all pivotal in dispensing Finasteride to the population. Market growth is largely driven by the aging demographic trend, increasing prevalence of androgenetic alopecia, and rising healthcare awareness, coupled with technological advancements in drug formulations. Latest opportunities for growth include expanding geographic access, especially in Asia-Pacific and Latin America, where healthcare infrastructure is improving. Companies could capitalize on this by engaging in strategic mergers to expand market presence. However, the Finasteride market is challenged by patent expirations and the availability of alternative therapies, which increase market competition. Additionally, side effects such as sexual dysfunction may limit its acceptance. Regulatory hurdles across various regions also pose challenges. Promising areas of innovation include developing advanced delivery systems to improve the drug's efficacy and minimize side effects, exploring combination therapies for enhanced outcomes, and integrating AI-driven analytics for targeted marketing strategies. Furthermore, an increased focus on research concerning genetic predispositions to conditions treated with Finasteride could unlock new market segments. Overall, the Finasteride market is dynamic, with potential for growth through strategic expansion and innovation, yet it necessitates careful navigation of regulatory landscapes and consumer perceptions, ensuring a balanced approach to leverage its full market potential.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Finasteride Market

The Finasteride Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of androgenetic alopecia and prostate disorders
  • Supportive regulatory policies enhancing market accessibility
• Market Restraints
  • Raw material scarcity impacting production scalability
• Market Opportunities
  • Advancements in production technologies for finasteride
  • Significant expansion of finasteride in therapeutic applications
• Market Challenges
  • Shortage of skilled workforce

Porter's Five Forces: A Strategic Tool for Navigating the Finasteride Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Finasteride Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Finasteride Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Finasteride Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Finasteride Market

A detailed market share analysis in the Finasteride Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Finasteride Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Finasteride Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Finasteride Market

A strategic analysis of the Finasteride Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Finasteride Market, highlighting leading vendors and their innovative profiles. These include Accord Healthcare US. by Intas Pharmaceuticals, Apotex Inc., Aurobindo Pharma USA, Inc., Camber Pharmaceuticals, Inc. by Hetero Labs Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Endo, Inc., Hanmi Pharmaceutical Co., LTD., Merck KGaA, Niksan Life Sciences Private Limited, Sun Pharmaceutical Industries Limited, Teva Pharmaceuticals USA, Inc., Torrent Pharmaceuticals Ltd., Veru Inc., Viatris Inc., WELLONA PHARMACEUTICAL PRIVATE LIMITED, and Zydus Group..

Market Segmentation & Coverage

This research report categorizes the Finasteride Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Indication, market is studied across Androgenetic Alopecia and Benign Prostatic Hyperplasia.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of androgenetic alopecia and prostate disorders
    • 5.1.1.2. Supportive regulatory policies enhancing market accessibility
  • 5.1.2. Restraints
    • 5.1.2.1. Raw material scarcity impacting production scalability
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in production technologies for finasteride
    • 5.1.3.2. Significant expansion of finasteride in therapeutic applications
  • 5.1.4. Challenges
    • 5.1.4.1. Shortage of skilled workforce
• 5.2. Market Segmentation Analysis
  • 5.2.1. Indication: High adoption of finasteride in androgenetic alopecia a long-term treatment option
  • 5.2.2. Distribution Channel: Emergence of online pharmacies as a convenient option for patients seeking privacy and ease
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Finasteride Market, by Indication

• 6.1. Introduction
• 6.2. Androgenetic Alopecia
• 6.3. Benign Prostatic Hyperplasia

7. Finasteride Market, by Distribution Channel

• 7.1. Introduction
• 7.2. Hospital Pharmacies
• 7.3. Online Pharmacies
• 7.4. Retail Pharmacies

8. Americas Finasteride Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Finasteride Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Finasteride Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
  • 11.3.1. Zydus Secures USFDA Approval for Finasteride and Tadalafil Capsules
  • 11.3.2. Zydus Lifesciences Expands Its Global Reach with Acquisition of UK-Based Liqmeds Group
  • 11.3.3. Blue Water Vaccines Acquires Verus Pharmaceuticals' Entadfi Capsules Division
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Accord Healthcare US. by Intas Pharmaceuticals
• 2. Apotex Inc.
• 3. Aurobindo Pharma USA, Inc.
• 4. Camber Pharmaceuticals, Inc. by Hetero Labs Limited
• 5. Cipla Limited
• 6. Dr. Reddy's Laboratories Ltd.
• 7. Endo, Inc.
• 8. Hanmi Pharmaceutical Co., LTD.
• 9. Merck KGaA
• 10. Niksan Life Sciences Private Limited
• 11. Sun Pharmaceutical Industries Limited
• 12. Teva Pharmaceuticals USA, Inc.
• 13. Torrent Pharmaceuticals Ltd.
• 14. Veru Inc.
• 15. Viatris Inc.
• 16. WELLONA PHARMACEUTICAL PRIVATE LIMITED
• 17. Zydus Group.